Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05829629Phase 1Recruiting

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Role: lead

NCT04528407Completed

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects

Role: lead

NCT06589609Phase 1Recruiting

Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

Role: lead

NCT04490512Phase 1Completed

Study of FluBHPVE6E7 in HPV-16 Infected Women

Role: lead

All 4 trials loaded